Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.89 on Tuesday. The stock has a fifty day moving average price of $1.25 and a 200 day moving average price of $1.45. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24. The company has a market cap of $58.96 million, a PE ratio of -1.36 and a beta of 0.10.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in Actinium Pharmaceuticals during the third quarter worth about $112,000. XTX Topco Ltd acquired a new position in Actinium Pharmaceuticals during the 3rd quarter worth approximately $268,000. Barclays PLC raised its stake in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after buying an additional 32,784 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Actinium Pharmaceuticals in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).